Insect Cell Line Parvoviral Vector Production Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved methods and systems to achieve high-yield, robust, and scalable production of parvoviral vectors in cells, particularly to overcome the limitations associated with process robustness in large-scale production.
Innovation Solution
The development of an insect cell line with integrated promoters and enhancer elements that regulate the expression of parvoviral Rep and capsid proteins, utilizing baculoviral vectors and transcriptional transregulators to enhance the stability and productivity of parvoviral vector production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If repeated homologous sequences are used in baculoviral vectors for protein production, then high protein expression levels are achieved, but instability of production levels occurs due to recombination between repeated sequences
Solution Approach 1:
The patent divides the expression system into multiple independent baculoviral vectors, each containing a single copy of the gene of interest under the control of different promoters (e.g., polyhedrin, p10, p6.9). This segmentation eliminates recombination between repeated sequences while maintaining high expression levels through the combined action of multiple vectors.
Solution Approach 2:
The patent changes the parameters of the expression system by using different promoters with varying induction kinetics and expression strengths. This allows optimization of both productivity and stability by selecting promoters that are less prone to recombination while still achieving high protein expression.
2Reliability
If mammalian production systems are used for AAV production, then high quality vectors are produced, but scaling up requires excessive bioreactor space
Solution Approach 1:
The patent uses insect cells as an intermediary system that bridges the gap between mammalian and bacterial production systems. Insect cells provide eukaryotic post-translational modifications and protein folding capabilities similar to mammalian cells, while being more scalable and cost-effective for large-scale production.
Solution Approach 2:
The patent optimizes expression parameters in insect cells by using different promoters and cultivation conditions to achieve vector qualities comparable to mammalian systems while enabling scalable production in smaller bioreactor volumes.
3Productivity
If Rep genes are expressed from single strong promoters in baculoviral vectors, then high Rep protein levels are achieved, but recombination between repeated sequences reduces vector stability
Solution Approach 1:
The patent segments the Rep gene expression into multiple baculoviral vectors, each with a single copy of the Rep gene under different promoter control. This eliminates the recombination problem associated with repeated sequences while maintaining high Rep protein levels through cumulative expression from multiple vectors.
Data Source
AI summary
The present invention relates to insect cell lines for the production of parvoviral gene therapy vectors. In particular the invention relates to stable insect cell lines with expression constructs for viral replicase proteins integrated into their genomes, which cell lines allow for high-yield, robust, and scalable production of heterologous parvoviral-related proteins and vectors.